From the Boardroom:Option to Purchase Deals

Practices: Venture Capital & Emerging Companies

Please join veteran life sciences professionals for an insider’s perspective on key considerations regarding option to purchase deals. Our panel of insiders will weigh in on a number of important questions and key issues that arise with this unique structure.

 
Confirmed speakers include:

  •  Mark Barrett – VP, Head of Strategy & Business Dev., Rare Diseases, Genzyme
  •  Evelyn Douglas – VP, Corporate Dev., Becton, Dickinson and Company
  •  Jon Glazer – Principal, Transaction Advisory Services, Ernst & Young
  •  Marko Zatylny – Partner, Ropes & Gray
  • Christopher Comeau - Partner, Ropes & Gray

Questions? Contact rgevents@ropesgray.com  

Attorneys

Cookie Settings